Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 9/20 | 0.39 |
| ▸ | MAOB | P27338 | 9/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PRNP | P04156 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1748533 | 0.85 | MAOA (0.54) | MAOAMAOBBRAFCYP1A2MEN1 | |
| SCHEMBL1747918 | 0.85 | MAOA (0.54) | MAOAMAOBCYP1A2MEN1KMT2A | |
| SCHEMBL3201555 | 0.81 | MAOA (0.51) | MAOAMAOBCYP1A2MEN1KMT2A | |
| SCHEMBL3196775 | 0.81 | MEN1 (0.40) | MAOAMAOBBRAFCYP1A2FGFR4 | |
| SCHEMBL3201640 | 0.81 | FGFR4 (0.41) | MAOAMAOBBRAFCYP1A2FGFR4 | |
| SCHEMBL1748776 | 0.81 | MAOA (0.42) | MAOAMAOBFGFR4NPC1RAB9A | |
| SCHEMBL1747929 | 0.81 | MAOA (0.42) | MAOAMAOBBRAFFGFR4NPC1 | |
| SCHEMBL3191800 | 0.80 | MAOA (0.50) | MAOAMAOBCYP1A2MEN1KMT2A | |
| SCHEMBL3194138 | 0.80 | EPHB4 (0.40) | MAOAMAOBBRAFFGFR4NPC1 | |
| Hydrochloric Acid SCHEMBL1748935 | 0.80 | MAOA (0.42) | MAOAMAOBFGFR4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968558-B2 | Amidine derivatives of 2-heteroaryl-quinazolines and quinolines; potent analgesics and anti-inflammatory agents | ROTTAPHARM S.P.A. (IT) | 2011-06-28 | — | — | US | disclosed |
| US-7968558-B2 | Amidine derivatives of 2-heteroaryl-quinazolines and quinolines; potent analgesics and anti-inflammatory agents | ROTTAPHARM S.P.A. (IT) | 2011-06-28 | — | — | US | disclosed |
| US-7968558-B2 | Amidine derivatives of 2-heteroaryl-quinazolines and quinolines; potent analgesics and anti-inflammatory agents | ROTTAPHARM S.P.A. (IT) | 2011-06-28 | — | — | US | disclosed |
| EP-2057148-B1 | AMIDINE DERIVATIVES OF 2-HETEROARYL-QUINAZOLINES AND QUINOLINES; POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | ROTTAPHARM SPA (IT) | 2009-12-30 | — | — | EP | disclosed |
| EP-2057148-B1 | AMIDINE DERIVATIVES OF 2-HETEROARYL-QUINAZOLINES AND QUINOLINES; POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | ROTTAPHARM SPA (IT) | 2009-12-30 | — | — | EP | disclosed |
| US-20090227609-A1 | AMIDINE DERIVATIVES OF 2-HETEROARYL-QUINAZOLINES AND QUINOLINES; POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | ROTTAPHARM S.P.A. (IT) | 2009-09-10 | — | — | US | disclosed |
| US-20090227609-A1 | AMIDINE DERIVATIVES OF 2-HETEROARYL-QUINAZOLINES AND QUINOLINES; POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | ROTTAPHARM S.P.A. (IT) | 2009-09-10 | — | — | US | disclosed |
| US-20090227609-A1 | AMIDINE DERIVATIVES OF 2-HETEROARYL-QUINAZOLINES AND QUINOLINES; POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | ROTTAPHARM S.P.A. (IT) | 2009-09-10 | — | — | US | disclosed |
| WO-2008014815-A1 | AMIDINE DERIVATIVES OF 2-HETEROARYL-QUINAZOLINES AND QUINOLINES; POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | ROTTAPHARM S.P.A. (IT) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227609-A1 | AMIDINE DERIVATIVES OF 2-HETEROARYL-QUINAZOLINES AND QUINOLINES; POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | NOS2, NOS3, NOS1 | MAOA 455/4885MAOB 414/4885BRAF 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.